

wdisk GP 1615  
BOX SEQ:

PATENT  
1340-1-017


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: ELAINE I. TUOMANEN ET AL.  
SERIAL NO.: 09/056,019 EXAMINER:  
FILED: April 7, 1998 ART UNIT: 1615  
FOR: A POLYPEPTIDE COMPRISING THE AMINO ACID OF AN N-TERMINAL CHOLINE BINDING PROTEIN A TRUNCATE, VACCINE DERIVED THEREFROM AND USES THEREOF

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on September 11, 1998.

Mark S. Cohen, Reg. No. 42,425  
(Name of Registered Representative)

  
(Signature)

**RECEIVED**

**SEP 18 1998**

MARSHALL, DUNNER,  
SERVICE CENTER

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Sir:

Responsive to the Notice dated April 22, 1998, and in accordance with 37 CFR 1.821-1.825, Applicants submit herewith the following:

1. A paper copy of a Sequence Listing for insertion into the Application as filed at the end of the Specification and prior to the Claims.
2. A copy of the Sequence Listing in computer readable form (ASCII text), submitted on a 3½" floppy disk compatible with IBM format.
3. A statement in support of the filing and submission of a Sequence Listing in accordance with 37 CFR 1.821 - 1.825.
4. A copy of the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

The time set for this response is September 22, 1998.

Applicants request favorable consideration and entry of the Sequence Listing submitted herewith and further and favorable processing of the present Application.

Applicants: ELAINE I. TUOMANEN ET AL.  
U.S. Serial No.: 09/056,019  
Filed: April 7, 1998  
Page 2


RECEIVED

SEP 18 1998

MARINA CUSTOMER  
SERVICE CENTER

Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,



Mark S. Cohen  
Attorney for Applicants  
Registration No. 42,425

KLAUBER & JACKSON  
411 Hackensack Avenue  
Hackensack, NJ 07601  
Tel: (201) 487-5800



PATENT  
1340-1-017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: ELAINE I. TUOMANEN ET AL.

SERIAL NO.: 09/056,019 EXAMINER:

FILED: April 7, 1998 ART UNIT: 1615

FOR: A POLYPEPTIDE COMPRISING THE AMINO ACID OF AN N-Terminal Choline Binding Protein A TRUNCATE, VACCINE DERIVED THEREFROM AND USES THEREOF

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on September 11, 1998.

Mark S. Cohen, Reg. No. 42,425  
(Name of Registered Representative)

  
(Signature)

STATEMENT IN SUPPORT OF THE FILING/SUBMISSION OF A  
NUCLEOTIDE/AMINO ACID SEQUENCE LISTING IN  
ACCORDANCE WITH 37 CFR §§1.821 - 1.825

ASSISTANT COMMISSIONER OF PATENTS  
WASHINGTON, DC 20231

Dear Sir:

YUAN KONG, hereby states as follows:

1. I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.
2. I hereby state that the submission, filed in accordance with 37 CFR §1.821(g) herein does not include new matter.
3. I hereby declare that all statements made herein of the undersigned's own

knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18 of the U.S. Code, Section 1001 and that such willful false statements may jeopardize the validity of this Application or any patent issuing thereon.

DATED:

9/11/98

  
YUAN KONG



Application No.: 1905019

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**